<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Contact Us Select Models
Select Models
organoid histo

Analytical Assays For Endpoint Data Collection

Translational TMAs for Oncology Research

Our Patient Derived Xenograft (PDX) Tissue Microarrays (TMAs) deliver more than static samples. They provide a functional starting point for integrated oncology research. By offering hundreds of PDX tumor cores per slide, our TMAs eliminate bottlenecks in early-phase validation and help scientists quickly identify which targets matter.

Overview

Why Choose Champions Translational TMAs?

Patient-Derived and Clinically Annotated

Assembled from our TumorGraft™ models, our TMA cores reflect Western clinical treatment history and come annotated with genomic and histopathologic data.

High-Content, Low-Variability Format

Each slide contains cores from a diverse patient cohort, reducing staining variability and enabling reliable IHC/IF analysis at scale.

Ready for IHC and Multiplexing

Built on FFPE format, our TMAs are compatible with standard histology workflows and multiplex biomarker readouts.

Pipeline-Linked, Not Standalone

TMAs are directly traceable to Champions' matched preclinical models, including PDX, and TumorGraft3D™ organoidsex vivo models, enabling immediate, functional follow-up.

Her2 IHC staining of a breast cancer TMA
HER2 IHC staining of a breast cancer TMA
54

What Comes Next

Translational Value Beyond the Slide

Each array isn't just a diagnostic snapshot, it's a launchpad. When a marker or expression pattern is identified, we enable seamless progression into:

  • Functional testing in TumorGraft3D™ or co-culture assays
  • Drug efficacy and combination studies in PDX or ex vivo systems

Using a prostate cancer-specific TMA, a client validated AR expression patterns across resistant patient samples, then used matched ex vivo models to test a dual inhibitor strategy. The result: clear translational direction in weeks, not months. 

Key Applications

  • Antibody validation and optimization
  • Biomarker discovery and target expression mapping
  • Indication stratification and tissue profiling
  • Preclinical immuno-oncology screening and hypothesis testing

Available Arrays

  • Broad coverage of solid and hematologic tumors
  • Rare and treatment-resistant cancer types
  • Large inventory available off-the-shelf
organoid histo

Get started

Request Our TMA Catalog

Contact our team to request a full catalog or discuss a custom array design based on your research needs and preferred indications.

FAQs

Frequently Asked Questions

The tumor microarray (TMA) technique involves extracting small, cylindrical tissue cores from tumor blocks and embedding them in a single recipient paraffin block. This allows simultaneous histological analysis of hundreds of samples under identical experimental conditions. 

Tissue microarrays are primarily used for high-throughput biomarker screening, target validation, and comparative tissue profiling. They help researchers analyze large cohorts of tumor samples efficiently and cost-effectively. 

TMAs can reveal patterns of protein expression, target prevalence, and biomarker distribution across diverse tumor types and patient samples. This enables insight into tumor heterogeneity, resistance markers, and therapeutic relevance. 

While TMAs offer scalability and consistency, they may underrepresent intratumoral heterogeneity due to the small core size. Additionally, sample dropout or damage during processing can occasionally limit full slide utility. 

Champions' Translational TMAs are directly linked to functional tumor models (PDX, ex vivo, TumorGraft3D™), enabling follow-up validation beyond the slide. Our arrays are also clinically annotated and reflect Western treatment profiles, making them more relevant for translational research. 

We offer arrays spanning common and rare solid tumors, as well as hematologic malignancies. Indications include breast, prostate, lung, colorectal, melanoma, ovarian, DLBCL, and more. 

Yes. All of our TMAs are FFPE-based and compatible with standard IHC, and multiplex staining protocols. 

Absolutely. TMAs are an ideal tool for antibody specificity and sensitivity validation across diverse tumor backgrounds before transitioning to in vivo or functional studies. 

Each TMA core in our platform is traceable to matched preclinical models. Once a target is identified, our scientific team can guide you into follow-up studies using PDX, ex vivo, or 3D multiclonal assays. 

You can contact our team to request a full catalog or discuss a custom array design based on your research needs and preferred indications.